Related Experiment Videos
Considerations when analyzing the methylation status of PTEN tumor suppressor gene
Michele A Zysman1, William B Chapman, Bharati Bapat
1Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Abstract:
Epigenetic mechanisms of gene silencing, including promoter hypermethylation of tumor suppressor genes, have been shown to contribute to tumorigenesis. PTEN is an important tumor suppressor implicated in the pathogenesis of a number of familial and sporadic cancers. Germline mutations of PTEN predispose to dominantly inherited hamartomatous disorders Cowden syndrome and Bannayan-Zonana syndrome. Somatic PTEN mutations commonly occur in endometrial, breast, prostate, and thyroid tumors. Several investigators have speculated on PTEN promoter hypermethylation as a possible mechanism of PTEN inactivation but data supporting such observations is not forthcoming. The genomic sequence of PTEN is 98% identical to a highly conserved processed PTEN pseudogene (psiPTEN) and this sequence identity extends 841 base pairs into the promoter region. This high degree of homology has made analysis of the methylation status of the PTEN promoter quite challenging. We have investigated the methylation profiles of the promoter region of PTEN in endometrial, breast, and colon cancer cell lines, as well as in a panel of primary endometrial tumors using a combination of methylation-specific polymerase chain reaction, methylation-sensitive restriction analysis, and bisulfite sequencing. Our results show that the pseudogene, and not PTEN, is predominantly methylated in cell lines and tumors. Without careful consideration of the critical nucleotide differences between the two sequences, results obtained from PTEN analysis may not necessarily represent the methylation status of PTEN.
Insights
PTEN promoter hypermethylation is often speculated as a cause of cancer. However, this study reveals that the highly similar PTEN pseudogene, not PTEN itself, is predominantly methylated in tumors.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic gene silencing, particularly promoter hypermethylation of tumor suppressor genes, contributes to cancer development.
- PTEN is a critical tumor suppressor gene involved in various cancers, with both germline and somatic mutations observed.
- Previous studies suggested PTEN promoter hypermethylation as a mechanism for PTEN inactivation, but conclusive data was lacking.
Purpose of the Study:
- To investigate the methylation status of the PTEN promoter region in various cancer types.
- To address the challenges in analyzing PTEN methylation due to its high homology with a processed pseudogene (psiPTEN).
Main Methods:
- Utilized methylation-specific polymerase chain reaction (PCR), methylation-sensitive restriction analysis, and bisulfite sequencing.
- Analyzed methylation profiles in endometrial, breast, and colon cancer cell lines, and primary endometrial tumors.
- Carefully considered nucleotide differences between PTEN and its pseudogene.
Main Results:
- The PTEN pseudogene (psiPTEN), not the PTEN gene, was found to be predominantly methylated in the analyzed cancer cell lines and tumors.
- High sequence homology (98%) between PTEN and psiPTEN, extending into the promoter region, complicated previous analyses.
Conclusions:
- The methylation observed in previous studies of the PTEN promoter was likely due to the methylation of the PTEN pseudogene.
- Accurate assessment of PTEN methylation requires careful differentiation from its highly homologous pseudogene to avoid misinterpretation of PTEN inactivation mechanisms.